<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00821392</url>
  </required_header>
  <id_info>
    <org_study_id>TMX-67</org_study_id>
    <nct_id>NCT00821392</nct_id>
  </id_info>
  <brief_title>Phase III Trial of Febuxostat in Korea Gout Patients</brief_title>
  <official_title>A Randomized, Multi-Center, Double Blinded, Allopurinol-Controlled, Placebo-Controlled Parallel Group, 5-Arm, Dose-Response,Bridging Study to Assess the Efficacy and Safety of Febuxostat in Subject With Gout</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SK Chemicals Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SK Chemicals Co.,Ltd.</source>
  <brief_summary>
    <textblock>
      This study was designed to evalute the efficacy and safety of Febuxostat after oral
      administration to patientd with gout in Korea
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, randomized, double-blind, allopurinol and placebo controlled,
      parallel, 5 arms, dose response, bridging study of 4 weeks duration.

      If subjects pass the screening evaluation after submitting a signed informed consent, they
      will be randomly assigned to one of the five treatment regimens; febuxostat 40mg, 80mg,
      120mg, placebo or allopurinol 300mg. Colchicine 0.6mg QDis given to minimize the risk of gout
      flares during the washout/run-in period and during the double study period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">181</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>1 Febuxostat 40mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Febuxostat 80mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3 Febuxostat 120mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4 Allopurinol 300mg</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Febuxostat</intervention_name>
    <arm_group_label>1 Febuxostat 40mg</arm_group_label>
    <arm_group_label>2 Febuxostat 80mg</arm_group_label>
    <arm_group_label>3 Febuxostat 120mg</arm_group_label>
    <arm_group_label>4 Allopurinol 300mg</arm_group_label>
    <arm_group_label>5 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        &lt;Day -14&gt;

          1. age :18-85 years

          2. female: either post-menopausal for at least 2 years, surgically sterile, or using a
             medically accepted means of contraception

          3. female: negative serum pregnancy test

          4. subjects who satisfy ARA (American Rheumatism Association)

          5. subjects must have a renal function defined as: serum creatinine ≤ 1.5 mg/dL &lt;Day -1&gt;

        1.serum urate level ≥8.0mg/dL 2.creatinine level ≤ 1.5mg/dL 3.subject continued to meet all
        inclusion and no exclusion criteria

        Exclusion Criteria:

          1. women who are breast-feeding or pregnant

          2. a history of xanthinuria

          3. allopurinol intolerance

          4. receiving thiazide diuretic therapy

          5. secondary hyperuricemia

          6. required &gt; 10mg/day of prednisone during the study stable dose(≤10mg/day), inhaled and
             intranasal steroids will be allowed.

          7. concomitant therapy containing aspirin or other salicylates(systemic or topical,
             prescribed or non-prescribed) stable, low doses aspirin will be allowed(i.e.
             ≤325mg/day).

          8. any change in hormone replacement therapy or oral contraceptive therapy within 3
             months of the screening visit

          9. alcohol intake≥ 14drinks/week alcohol abuse within 5 years or current excessive
             alcohol use was prohibited.

         10. concomitant therapy with any urate-lowering therapy

         11. active liver disease or hepatic dysfunction : ALT, AST ≥1.5 ULN

         12. subject was unable to take colchicine or contradictory to colchicine

         13. a serum urate level &lt; 8.0mg/dL and not taking uric acid lowering therapy

         14. rheumatoid arthritis or any active arthritis requiring for the medication treatment

         15. a history of cancer (other than basal cell carcinoma of the skin) within 5 years prior
             to the screening visit, or had taken any systemic cancer chemotherapy within 5 years
             prior to the screening visit

         16. participated in another investigational trial within the 30days prior to the screening
             visit

         17. any other significant medical condition as defined by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2009</study_first_submitted>
  <study_first_submitted_qc>January 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2009</study_first_posted>
  <last_update_submitted>January 12, 2009</last_update_submitted>
  <last_update_submitted_qc>January 12, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2009</last_update_posted>
  <responsible_party>
    <name_title>SK Chemicals Co.,Ltd.</name_title>
    <organization>SK Chemicals Co.,Ltd.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Febuxostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

